Mdh Hospice,the 525 E Grant St, Macomb, IL, 61455 | |
(309) 836-1543 |
News Archive
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.
Scientists are using the latest imaging techniques usually used to map the brain to try and understand why some pregnant women miscarry or go into early labor.
Women are significantly less likely than men to undergo coronary artery bypass grafting (CABG) using guideline-recommended approaches, which may result in worse outcomes after surgery, according to a scientific presentation at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Researchers have identified a possible new treatment for gonorrhea, using a peptide that thwarts the infection-causing bacterium by interfering with an enzyme the microbe needs to respirate.
› Verified 1 days ago
Name | Mdh Hospice,the |
---|---|
Location | 525 E Grant St, Macomb, Illinois |
Hospice ID | 141524 |
Category | Part of a hospital |
Ownership Type | Government - County |
Profit Type | GEVERNMENT |
SSA county code | 630 |
News Archive
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.
Scientists are using the latest imaging techniques usually used to map the brain to try and understand why some pregnant women miscarry or go into early labor.
Women are significantly less likely than men to undergo coronary artery bypass grafting (CABG) using guideline-recommended approaches, which may result in worse outcomes after surgery, according to a scientific presentation at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Researchers have identified a possible new treatment for gonorrhea, using a peptide that thwarts the infection-causing bacterium by interfering with an enzyme the microbe needs to respirate.
› Verified 1 days ago
NPI Number | 1467410282 |
Organization Name | Mcdonough County Hospital District |
Address | 525 E Grant St Macomb, Illinois, 61455 |
Phone Number | (309)833-4101 |
News Archive
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.
Scientists are using the latest imaging techniques usually used to map the brain to try and understand why some pregnant women miscarry or go into early labor.
Women are significantly less likely than men to undergo coronary artery bypass grafting (CABG) using guideline-recommended approaches, which may result in worse outcomes after surgery, according to a scientific presentation at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Researchers have identified a possible new treatment for gonorrhea, using a peptide that thwarts the infection-causing bacterium by interfering with an enzyme the microbe needs to respirate.
› Verified 1 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 98.6 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 75.8 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 93.7 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 98.3 | 93.3 |
News Archive
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.
Scientists are using the latest imaging techniques usually used to map the brain to try and understand why some pregnant women miscarry or go into early labor.
Women are significantly less likely than men to undergo coronary artery bypass grafting (CABG) using guideline-recommended approaches, which may result in worse outcomes after surgery, according to a scientific presentation at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Researchers have identified a possible new treatment for gonorrhea, using a peptide that thwarts the infection-causing bacterium by interfering with an enzyme the microbe needs to respirate.
› Verified 1 days ago
Home Health Aides | 4 |
Medical Social Workers | 2 |
Physicians | 2 |
Registered Nurses | 6 |
Total Employees | 14 |
---|
News Archive
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.
Scientists are using the latest imaging techniques usually used to map the brain to try and understand why some pregnant women miscarry or go into early labor.
Women are significantly less likely than men to undergo coronary artery bypass grafting (CABG) using guideline-recommended approaches, which may result in worse outcomes after surgery, according to a scientific presentation at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Researchers have identified a possible new treatment for gonorrhea, using a peptide that thwarts the infection-causing bacterium by interfering with an enzyme the microbe needs to respirate.
› Verified 1 days ago
Mdh Hospice,the Location: 525 E Grant St, Macomb, Illinois, 61455 Phone: (309) 836-1543 |